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 Our adjusted correlation factor is: 
 
 To obtain the calibrated image, the PVrI is divided by this factor, 
converted into ODrI, divided by ODbI and finally DCC is applied. 
Conclusions: This method was applied for several beam configurations 
placing EBT2 films in different phantoms. Dose planes obtained were 
compared to equivalent measures obtained with PTW 2D-ARRAY 
seven29 and to calculated data from CMS XiO TPS. PTW Verisoft was 
used to calculate Gamma2D planes and in all cases the gamma index 
(3%, 3 mm) was below 1 for at least 95% of points. There is also a good 
agreement between the absolute doses measured at different points 
of the film with measurements made with IC. Differences are less than 
3%. 
REF. (1) A. Micke, D. Lewis and X. Yu, 'Multichannel film dosimetry with 
nonuniformity correction', Med. Phys. 38(5), 2523-2534, (2011). 
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Purpose/Objective: Pre-treatment verification of radiation plans is an 
important part of the quality assurance program. None of advanced 
treatment techniques could be applied without the guarantee that the 
delivered dose is coincided with the planning dose at a level of the 
IAEA recommendations. This analysis can be performed by the means 
of the electronic portal imaging device (EPID). The method of the 3D 
dosimetric verification of the volumetric-modulated arc therapy 
(VMAT) plans based on EPID was studied. 
Materials and Methods: It was investigated about 50 radiation 
treatment plans for the SBRT patients with non-small cell lung cancer 
(NSCLC), pulmonary metastasis, prostate cancer, head-and-neck 
tumors and brain lesions, which were treated in the Centre for 
Stereotactic Radiotherapy and Radiosurgery in Novosibirsk Research 
Institute for Circulation Pathology. During a complete treatment 
simulation at the linac the portal dose images (PDI) were received for 
each patient field and compared with the planned PDIs. 3D dosimetric 
verification was performed for all patient plans calculated according 
with the volumetric-modulated arc therapy (VMAT). The procedure 
fulfilled using the IViewGT electronic portal imaging device (EPID) and 
Dosimetry Check software. The plans were verified by comparison the 
isodose lines, 2D profiles, dose volume histograms and γ-analysis. 
Results: The planned and reconstructed dose distributions showed 
good agreement for pre-treatment verification of the VMAT plans. The 
average planned and measured isocentre dose difference was 1.20% 
(range 0.07–2.56%). 3D γ-analysis revealed γmean= 0.28 for lung 
metastasis, 0.32 for lung SBRT, 0.33 for prostate, 0.33 for brain 
lesions and 0.39 for head-and-neck tumors. The passing criteria for 
the treatment plans was established for the head-and-neck tumors 
within P% = 90% (γ ≤ 1) and within P% = 95% (γ ≤ 1) for other considered 
localizations. 
Conclusions: Verification method on the base of electronic portal 
imaging device has been successfully implemented. EPID can be used 
for the high accuracy, high resolution and fast routine pre-treatment 
verification of VMAT treatment plans.  
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Purpose/Objective: The purpose of this study was to evaluate an 
absolute pre-treatment verification method for Cyberknife therapy 
with a PinPoint ionization chamber and radiochromic EBT3 films. 
Materials and Methods: The CT scan of the Easy cube Phantom was 
acquired with the clinical parameters used for Cyberknife patients; 
the PinPoint ionization chamber and radiochromic film were 
positioned in the centre of the phantom. Eight fiducial markers were 
previously inserted into the phantom for treatment set-up. A fiducial 
tracking method was used for template QA plan: the patient’s plan 
was recalculated on the Easy Cube phantom and centred in the 
sensitive volume of the Pin Point ionization chamber. The dose was 
calculated with Ray-Tracing algorithm. The radiochromic EBT3 films 
were properly calibrated with a 6 MV linear accelerator (Clinac 600, 
Varian), delivering dose from 0 Gy to 10 Gy with 12 dose points. A 
total of 137 patients were evaluated: 91 patients with the PinPoint 
chamber only and 46 patients with PinPoint chamber and radiochromic 
film.  
Absolute dose measured with the PinPoint chamber was compared 
with the mean dose calculated in the sensitive volume of the chamber 
from the treatment planning system. The radiochromic films were 
scanned using a Epson 1000XL in transmission mode, 48 bit colour and 
resolution of 72 dpi. For each patient, calculated and measured axial 
planar dose distribution was compared with the Gamma Analysis 
Method (3% dose difference and 3 mm distance to agreement criteria) 
performed by the VeriSoft Program (PTW). 
Results: The percentage differences between calculated and 
measured PinPoint absolute dose ranges from -7.2 to 9.1 with a mean 
value of 4.8±4.1, resulting to be below 5% in the 73.9% of cases. The 
percentage of patients passing the gamma analysis (90% of pixels 
exceeding a 3% and 3 mm threshold) was 84.8%. 
Conclusions: The results obtained with PinPoint measurements show a 
good agreement between calculated and measured absolute dose. 
Preliminary results obtained with radiochromic films show some 
critical aspects. Further investigations regarding the possible 
employment of a 2D-array are required in order to perform the 
comparison between calculated and measured axial planar dose 
distribution with the possibility to speed up the procedures of QA 
program. 
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Purpose/Objective: The DAVID is an optically-transparent, 
transmission-style detector composed of two sheets of Perspex 
enclosing a vented air gap. The gap contains a series of collection 
wires running in the direction of the MLC leaf movement; each wire is 
held at a potential and is aligned with an individual MLC leaf pair. The 
signal generated at each wire is proportional to the radiation fluence 
through its associated leaf pair; with additional components from 
adjacent leaf apertures, due to scatter inside the Perspex. The 
current paradigm for using the DAVID, as an in-vivo device, is to 
record a DAVID signal during the pre-treatment verification of 
treatment delivery to a phantom; should the treatment pass the 
verification, the DAVID signal will be used as a baseline to compare 
the subsequent in-vivo responses for each treatment fraction. A new 
procedure has been suggested, where the treatment is verified using 
independent checking software; if the treatment passes this test, the 
information held by the independent software is then used to 
generate a DAVID signal, which can be used as a baseline for the 
subsequent in-vivo measurements. The independent dose check and 
generation of a baseline signal for in-vivo measurements provides a 
safe system that will catch errors in the TPS, plan transfer to the 
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delivery system and treatment delivery by the linac. This work is 
concerned with developing an algorithm to predict the DAVID signal.  
Materials and Methods: The lateral response resulting from the 
primary and scattered radiation was characterised. Convolution of the 
lateral response with the leaf separations of each segment in a step-
and-shoot plan, combined with additional corrections for leaf leakage 
and penumbral drop-off, result in anticipated signals for each wire. 
This simple approach was used to predict the signal for a range of 
clinical head and neck IMRT plans. The DAVID signal for each of the 
plans was collected five times and the results averaged. These were 
then compared to the predicted signals. The percentage difference 
between the maximum predicted and measured signals was calculated 
for the whole treatment; differences >5% resulted in a failed delivery. 
Providing this initial test was passed, a set value of 5% of maximum 
result (either predicted or measured – whichever was lower) was used 
to assess the difference between all the predicted and measured 
values for each wire, for each field – results with differences greater 
than this set value resulted in a failed delivery. 
Results: All the treatments passed. The algorithm was also able to 
detect artificially-induced changes in MU delivery of 5% and greater, 
to the extent that the treatment delivery 'failed'. 
Conclusions: The work has shown that a simple algorithm – 
calculations take <5s – can be used to accurately predict the response 
of the DAVID. Using the procedure discussed above, enables in-vivo 
verification of dose and delivery of IMRT treatments that is quick, 
easy and does not require separate pre-treatment time on the 
treatment unit. 
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Purpose/Objective: EPIDs has been in use for patient specific pre-
treatment QA of static IMRT (fixed doserate and gantry) at dep. of 
Radiotherapy, Herlev Hospital and has performed satisfactory. 
However for VMAT QA discrepancy above tolerance between expected 
and measured fluence is recurring. The purpose of this study was to  
1) Compare EPID statistics to Scandidos Δ4^pt to check for correlation 
2) quantify and characterize the observed discrepancy  
A comparative statistical study was carried out to reveal correlation 
between two different systems forpatient specific pre-treatment QA 
of VMAT.  
Any such correlation would be sign of true error i.e in either the 
fluence delivered or the one predicted by the TPS. 
It was found that the portal dose images (PDI) exhibit a systematic 
discrepancy from the predicted,e.g the measured 'dose' is 
systematically higher.  
Materials and Methods: 69 clinical plans were verified using both the 
EPID and phantom-detector array systems for comparison. All plans 
were created and calculated in Varian ECLISPE TPS and delivered by 
Varian 2300 iX Clinac,with a max. doserate of 600 MU/min, calibration 
as recommend by manufacturer. The EPID used was a 
VarianPortalVision aS1000. The Δ4^pt system consists of a cylindrical 
PMMA phantom with 1069 p-Si detectors in two perpendicular plane 
arrays inside, measuring absorbed dose (hence measuring fluence 
indirectly). Statistics was obtained on the gamma passing rate of the 
plans using the two systems with criteria of3% dose dev. and 3mm DTA 
as well as 3%/2mm. The characterization of the systematic 
discrepancy was obtained by tuning the scale of measured PDIs to 
match the dose profiles (predicted and measured) maximally. This can 
be done in Portal Dosimetry with the normalization of the images set 
to relative mode (predicted dose for reference), so that the calibrated 
unit is omitted.  
Results: For the plans studied, the mean value of the γ passing rate 
was obtained, as seen in Table 1; almost all plans had two full arcs 
(G1 + G2), each measured individually.  
 Measured with Δ4, the <γ> and standard deviation, σ, shows good 
agreement between expected and measured dose (<γ3%3mm >=99.9 % ) 
and hence also fluence.The EPID measurements exhibit poorer 
agreement (<γ3%3mm>=99.9 %) and a much larger spread in the values 
(σ ~10%). 
After tuning each image to an individual modification factor, Φ, the 
<γ> is much closer to 100% agreement with <γ2%2mm >=98.5 %. The 
mean value of the factor Φ is ~96%. 
Conclusions: The systematic discrepancy between the EPID predicted 
and measured fluence was not confirmed by the Δ4^pt measurements. 
The factor modification (tuning down) resulting in very good 
agreement between expected and measured images can be 
interpreted as a sign that the calibration of the EPID as recommended 
by the manufacturer is not quite appropriate for pre-treatment QA of 
VMAT. An investigation of the systematic discrepany as to wether it 
depends on e.g. treatment site specific parameters is ongoing.  
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Purpose/Objective: TQA is a group of software modules released by 
Tomotherapy to monitor the performance of Tomotherapy machines. 
In this work, two areas are investigated: (a) the correlation between 
the energy variation of TomoTherapy Tomo HD system and data trends 
present in TQA modules; and (b) TQA data trends for predicting 
magnetron failure. 
Materials and Methods: The energy variation of a Tomo HD system 
was studied. Exit Detector Flatness from Basic Dosimetry is the root-
mean square of the normalized cone ratio, and was compared with 
the percentage depth dose (PDD) data collected weekly using a 
standard energy constancy check procedure. Pearson’s correlation 
coefficient r was used to examine the inter-correlation of quantities 
recorded in TQA modules and their relation to PDD. Pulse-by-
PulseDose1 in Basic Dosimetry and output variation as measured by 
monitor chamber 1 before and after each magnetron replacement 
were compared. Running averages and cumulative standard deviations 
for Pulse-by-Pulse Dose1 throughout the lifetime of each magnetron 
were studied for clues of any sudden degradations of the magnetron. 
Data were collected over a minimum period of 9 months from three 
Tomo HD systems. 
Results: The plot of Exit Detector Flatness versus PDD20cm/PDD10cm 
demonstrated a linear correlation between the two quantities. The 
strong correlation was evident in that r = 0.945. Energy Differences in 
two TQA modules are measured with the aluminum step wedge, and 
they also showed strong indication of any energy drifts in the 
machine. The mean for Pulse-by-Pulse Dose1, which shows the output 
variation as measured by monitor chamber 1, generally decreased 
after a magnetron replacement. The running mean and cumulative 
standard deviation for Pulse-by-Pulse Dose1 showed no predictable 
pattern as the magnetron aged. Among the 9 cases of magnetron 
failure in record, 6 were observed to display abnormal waveforms in 
